ValuEngine lowered shares of Summit Therapeutics PLC (NASDAQ:SMMT) from a hold rating to a sell rating in a research report sent to investors on Thursday morning.

Several other equities research analysts have also commented on SMMT. Canaccord Genuity restated a buy rating and issued a $28.00 price target on shares of Summit Therapeutics PLC in a report on Friday, June 16th. Oppenheimer Holdings, Inc. set a $24.00 price target on shares of Summit Therapeutics PLC and gave the company a buy rating in a report on Thursday, June 22nd. Finally, Zacks Investment Research lowered shares of Summit Therapeutics PLC from a strong-buy rating to a hold rating in a report on Wednesday, September 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $23.50.

Shares of Summit Therapeutics PLC (SMMT) traded down 0.23% during trading on Thursday, hitting $12.76. 26,739 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $13.02 and a 200-day moving average price of $13.02. The stock’s market cap is $158.03 million. Summit Therapeutics PLC has a one year low of $7.95 and a one year high of $16.86.

Summit Therapeutics PLC (NASDAQ:SMMT) last released its quarterly earnings data on Thursday, August 31st. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.28). The company had revenue of $25.01 million during the quarter, compared to analysts’ expectations of $31.37 million. Summit Therapeutics PLC had a negative net margin of 12.44% and a negative return on equity of 29,334.40%. Equities research analysts expect that Summit Therapeutics PLC will post ($0.11) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Summit Therapeutics PLC (SMMT) Cut to “Sell” at ValuEngine” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at

An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Renaissance Technologies LLC purchased a new stake in Summit Therapeutics PLC (NASDAQ:SMMT) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 20,102 shares of the company’s stock, valued at approximately $267,000. Renaissance Technologies LLC owned approximately 0.16% of Summit Therapeutics PLC as of its most recent filing with the SEC. Hedge funds and other institutional investors own 21.77% of the company’s stock.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.